BRAF and neoplasm: Tumor mutational burden (TMB; evaluated only in patients treated with tobemstomig and nivolumab plus ipilimumab based on favorable efficacy results) and the prevalence of BRAF V600E and V600K mutations were similar in patients in the tobemstomig arm and the nivolumab plus ipilimumab arm.